- Tytuł:
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
- Autorzy:
- Źródło:
- In The Lancet Neurology September 2021 20(9):729-738
Czasopismo naukowe